Starpharma to present DEP at Radiopharmaceuticals Summit
Released
Released
Announcement PDF
Starpharma to present DEP® at Radiopharmaceuticals Summit
Melbourne, Australia; 6 December 2023: Starpharma (ASX: SPL, OTCQX: SPHRY) today
announces it is presenting at the Targeted Radiopharmaceuticals Summit Europe, having
been invited to present at the specialist radiotheranostics conference being held in Berlin,
Germany, from 5 to 7 December 2023.
The Targeted Radiopharmaceuticals Summit also includes speakers from Novartis, Bayer,
Bicycle Therapeutics, AstraZeneca, Bristol-Myers Squibb, Precirix, Telix, and Fusion
Pharmaceuticals. The Summit brings together professionals to provide insights into the
research, development, and commercialisation of radiopharmaceuticals, including novel
targets and combination therapies.
Starpharma’s Vice President of Development and Regulatory Affairs, Dr Jeremy Paull, will
deliver a presentation on the application of Starpharma’s DEP® platform for precision cancer
radiotheranostics, including:
•
the application, versatility, and benefits of the DEP® platform for targeted delivery of
radiotheranostics; and
•
an overview of Starpharma’s two DEP® HER2-targeted radiotheranostic products,
DEP® HER2-zirconium and DEP® HER2-lutetium.
Starpharma recently reported data on DEP® HER2-zirconium, a HER2-targeted
radiodiagnostic candidate, demonstrating excellent tumour accumulation, a favourable
biodistribution profile, with excellent imaging contrast between tumour and normal tissues, as
well as rapid uptake in a HER+ breast cancer model. Starpharma’s radiotherapeutic product,
DEP® HER2-lutetium, has shown excellent anticancer activity, outperforming Herceptin®
labelled with lutetium, in a human breast cancer model. These products are designed to assist
in improving the diagnosis, staging, monitoring, and treatment of HER2+ cancers, which
include breast and upper gastro-intestinal cancers. The data reported in the presentation have
been generated from studies conducted in collaboration with the Monash Institute of
Pharmaceutical Sciences (MIPS) and the University of Queensland.
The conference presentation, ‘Branching Out: DEP® Dendrimer Nanoparticles as a Versatile
Platform for Precision Cancer Radiotheranostics’, will take place on 6 December 2023 in Berlin
as part of the Novel Targets stream.
A copy of the presentation is appended.
About Starpharma
Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) is a world leader in dendrimer technology for medical applications.
As an innovative Australian biopharmaceutical company, Starpharma is focused on developing and commercialising novel
therapeutic products that address significant global healthcare needs. Starpharma boasts a strong portfolio of products,
partnerships, and intellectual property.
Starpharma’s innovative technology is based on proprietary polymers called dendrimers, which are precise, synthetically
manufactured, nanoscale molecules. The unique properties of dendrimers – including their size, structure, high degree of
branching, polyvalency, and water solubility – are advantageous in medical and pharmaceutical applications.
Starpharma uses its dendrimer technology to develop novel therapeutics and to improve the performance of existing
pharmaceuticals. Starpharma’s portfolio includes multiple clinical-stage oncology products, which utilise its Dendrimer Enhanced
Product (‘DEP®’) drug delivery technology, and marketed products, including VIRALEZE™ and VivaGel® BV, which utilise
SPL7013, a proprietary dendrimer with antimicrobial properties.
Starpharma’s DEP® drug delivery platform is being used to enhance the effectiveness of existing and novel therapies and to
reduce drug-related toxicities through controlled and specified drug delivery.
In addition to Starpharma’s internal DEP® programs, Starpharma has multiple DEP® partnerships with international
biopharmaceutical companies, including AstraZeneca (oncology), MSD (Antibody-Drug Conjugates), Chase Sun (anti-infectives),
and other world-leading pharmaceutical companies. Due to the broad applicability and optionality of Starpharma’s DEP® platform,
partnered DEP® programs have the potential to generate significant future milestones and royalties.
Starpharma’s topical antiviral nasal spray, VIRALEZE™, is now registered in more than 35 countries*, including Europe, the UK,
and Asia. Starpharma’s novel non-antibiotic vaginal gel, VivaGel® BV, for the treatment of bacterial vaginosis (BV) and prevention
of recurrent BV, is registered in more than 50 countries, including in the UK, Europe, Southeast Asia, South Africa, Australia and
New Zealand.
For more information about Starpharma, visit www.starpharma.com or connect with Starpharma on LinkedIn.
WE Communications
Hannah Howlett
WE-AUStarPharma@weworldwide.com
Starpharma Holdings Limited
Dr Jackie Fairley, Chief Executive Officer
Justin Cahill, CFO and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
4-6 Southampton Crescent
Abbotsford Vic 3067
Disclosure
This ASX Announcement was
authorised for release by the
Chair, Mr Rob Thomas.
Forward Looking Statements
This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking
terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”,
“potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, “outlook”, or similar expressions, or by
express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forwardlooking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from
any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future
regulatory filings will satisfy the FDA’s and other authorities’ requirements regarding any one or more product candidates nor can there be any
assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of
sales. In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by,
among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays,
or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general;
government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products,
product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking
statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other
clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no
representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this
document nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past,
present or the future performance of any Starpharma product.
2
ASX: SPL
OTC: SPHRY
Branching Out: DEP® Dendrimer
Nanoparticles as a Versatile
Platform for Precision Cancer
Radiotheranostics
Jeremy Paull, PhD
VP, Development and Regulatory Affairs
5th Annual Targeted Radiopharmaceuticals Summit Europe
6 December 2023
Important notice and disclaimer
This document is intended for investors and market participants only. This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking
terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being
developed”, “could be”, “on track”, “outlook” or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forwardlooking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by
such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other health authorities’ requirements regarding any one or more product candidates, nor can there be
any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the
approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected
regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public
pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties
materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of
the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical
case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person
as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document, nor any information made available to you is or shall be relied upon as, a promise, representation, warranty or
guarantee as to the past, present or future performance of any Starpharma product.
Targeted Radiopharmaceuticals Summit Europe 2023
2
DEP® Dendrimers: A Versatile, Multifunctional Delivery
Platform for Precision Cancer Radiotheranostics
KEY MESSAGES
Proprietary DEP® platform – clinically validated via 4 clinical programs, multiple drug classes
Starpharma’s are the only marketed dendrimer-based products
DEP® platform:
provides flexibility for a wide range of payloads and chelating agents
can achieve preferential delivery to tumours by virtue of size
can also be functionalised to carry a wide range of targeting moieties
provides flexibility for customisation of biodistribution / excretion profile
Targeted DEP® can achieve improved biodistribution and efficacy profiles vs antibody targeting
DEP® DENDRIMERS: A VERSATILE, MULTIFUNCTIONAL PLATFORM FOR CUSTOMISATION OF
PRECISION RADIOTHERANOSTICS FOR CANCER IMAGING AND THERAPEUTIC APPLICATIONS
Targeted Radiopharmaceuticals Summit Europe 2023
3
Starpharma is an innovative biopharmaceutical
company and leader in dendrimer technology
Innovative drug / multifunctional delivery platform, DEP®
Proprietary nanoparticle platform; ability to create innovative therapies and enhance existing
drugs; significant optionality; accelerates path to market; and manages investment risk.
Deep portfolio of high-value assets
Three promising internal clinical-stage assets are under development: improved, patented
versions of widely used cancer medications and a strong pipeline of preclinical-stage assets,
including radiotheranostics.
Multiple products on market.
DEP®
Multiple global pharma partnerships
DEP® partnerships with three of the world’s top 10 pharmaceutical companies: MSD,
Genentech and AstraZeneca. Starpharma generates returns via research fees, milestones
and royalties. Funded by large pharma partners. DEP® platform offers the ability to partner
widely without Starpharma funding programs.
Strong financial position
Strong balance sheet and runway with $35.6 million cash at 30 September 2023, excluding
the $7.2 M R&D tax incentive refund received in October 2023.
SPL7013
Strong international institutional share register
Institutions include Allianz, UIL/ICM, Allan Gray, M&G, and Fidelity.
Targeted Radiopharmaceuticals Summit Europe 2023
4
Starpharma’s portfolio: multiple dendrimer-based clinicalstage assets, partnerships and products in market
DEP® Pipeline
Partnered DEP® Programs
Product
Target
indication
Preclinical
DEP®
cabazitaxel
Prostate and
other cancers
Phase 2 complete & results reported
DEP®
irinotecan
Colorectal and
other cancers
Phase 2 recruitment complete
DEP®
docetaxel
Pancreatic and
other cancers
Phase 2 recruitment complete
DEP® HER2 ADC
Solid cancers
DEP® HER2
radiotherapy
Solid cancers
DEP® HER2
radiodiagnostic
Diagnostic
Partnerships
Various
Phase 1
Phase 2
Two DEP® ADC Research
Agreements with MSD (Merck &
Co., Inc.)
Two DEP® Research Agreements
with Genentech
DEP® anti-infective research
partnership with Chase Sun
Multi-product DEP® licence with
AstraZeneca
Commercialised Products
VIRALEZE™ Antiviral
Nasal Spray
Targeted Radiopharmaceuticals Summit Europe 2023
VivaGel® BV
VivaGel® Condom
5
Starpharma's DEP® platform: highly versatile, enhancing the
commercial and therapeutic value of a wide range of drugs
Improved
Safety
/ Reduced
Effects
Multiple DEP® therapeutic areas across
partnered
and
internalSide
programs
DEP® technology:
•
•
•
Based on proprietary, branched polymers
called dendrimers
A platform with significant optionality –
applicable to many different drugs / payloads
Optimises drug properties and enables
targeted therapy, creating differentiated
products, managing a product’s lifecycle and
creating new intellectual property.
DEP® dendrimer-drug conjugate
Control release kinetics of drug to reduce Cmax-related toxicities
Improved Efficacy / Performance
DEP® achieves drug targeting, improved PK and controlled release
New IP / Extended Patent Life
DEP®
platform
benefits
DEP® creates new intellectual property and extends patent
life
Tumour Targeting
DEP® delivers 40-70x more drug in tumour cf. the
original drug
Improved PK and Half-life
Tuning of drug release and plasma half-life to improve
performance
Rx
DEP® dendrimer
radiotheranostic
Improved Solubility
Highly water-soluble, removing the need for toxic excipients
Broad Applicability
Applicable to a wide range of therapeutic areas and treatment modalities (e.g., radiotheranostics,
Antibody-Drug Conjugates (ADCs)).
Targeted Radiopharmaceuticals Summit Europe 2023
6
DEP® partnering creates significant commercial value
and optionality
® therapeutic areas across partnered and internal programs
Multiple
DEP
®
Benefits of DEP partnerships
Two DEP® ADC Research
Agreements with MSD
• Funded by partners
• Leverage existing and create
new intellectual property
• Broaden the applications of
DEP®, creating multiple
potential revenue streams
• DEP® platform offers
significant optionality and
leverage, enabling multiple
licenses to run in parallel
without Starpharma funding
programs
Starpharma’s
Expanding
DEP®
Partnerships
Two DEP® Research
Agreements with
Genentech
DEP® anti-infective
research partnership with
Chase Sun
Multiproduct DEP® licence
and Option agreement
with AstraZeneca
Starpharma’s DEP® platform enhances the commercial and therapeutic value of a wide range of
drugs, creating multiple potential revenue streams and significant IP leverage
Targeted Radiopharmaceuticals Summit Europe 2023
7
Starpharma’s DEP® platform has broad applicability,
creating multiple high-value commercial applications
Chemotherapeutics
Antibody-Drug Conjugates
• Franchise extension
• Generic differentiation
• New chemical entities
• Combinations including
immuno-oncology
• Flexible technology
• Increased drug antibody
ratio
• Targeting group agnostic
• Site selective payload
attachment
The DEP® platform can provide
therapeutic and commercial
value across a wide range of
therapeutic areas and treatment
modalities.
Radiotheranostics
Non-oncology
• Radiotheranostic
applications
• Can use a variety of
isotopes and targeting
approaches
• Applicable to antivirals
and anti-infectives
• Endocrinology
Targeted Radiopharmaceuticals Summit Europe 2023
8
DEP® platform versatility – flexible, precise, and scalable
DEP® Dendrimer
DEP® dendrimer
• Clinically validated
• Easily scalable, precisely manufactured, GMP
Drug / Payload
• Flexible – type and number of payload molecules
• Can deliver high “DAR” (4, 8, 16, etc.), no impact
on solubility
Linker /
Pharmacokinetics
• Payload release rate, plasma half-life tuneable
• Dendrimer size and charge can be altered to
regulate kidney glomerular filtration
Drug / Payload
Linker
PEG
Targeting moiety
Cytotoxic
Ultra-toxic
PEG
Targeting (Option)
• Provides stealth, controls clearance, solubility
• No observed adverse effects, ABC
• Flexible choice of targeting moiety (e.g., antibody,
antibody mimetics, peptide, small molecule)
• Polyvalency
Targeted Radiopharmaceuticals Summit Europe 2023
Chelator / Radioisotope
Immunomodulator
Insoluble drug
payload
DEP® solubilised
drug payload
9
Starpharma’s internal DEP® oncology portfolio
Multiple clinical-stage assets with high commercial value potential
DEP® cabazitaxel
Phase 2
DEP® cabazitaxel – dendrimer version of
leading prostate cancer drug, cabazitaxel
(Jevtana®)
Jevtana® global sales of ~US$500M for
2021 despite multiple US FDA “Black
Box” warnings
Advantages of DEP® cabazitaxel#*
Improved tolerability profile; detergentfree formulation; no steroid pretreatment; tumour-targeting, improved
efficacy; patent filings to 2039 (plus up to
an additional ~5 years)
COMMERCIAL
OBJECTIVE
Create value through
clinical proof-ofconcept (Phase 2)
# Clinical studies have demonstrated reduction in important
side effects with DEP® such as bone marrow toxicity,
anaphylaxis, severe diarrhoea and hair-loss
DEP® irinotecan
Phase 2
DEP® docetaxel
Phase 2
DEP® irinotecan – dendrimer version of
irinotecan (Camptosar®) – commonly
used to treat colorectal cancer
DEP® docetaxel – dendrimer
version of docetaxel (Taxotere®), which
is widely used to treat breast, lung and
prostate cancer
Camptosar® peak global sales of
US$1.1B despite multiple US FDA “Black
Box” warnings
Advantages of DEP® irinotecan#*
Tumour-targeting; DEP® solubilises
SN38 active metabolite and allows direct
dosing, avoiding need for liver
conversion – reduced toxicity, variability;
improved efficacy; patent filings to 2039
(plus up to an additional ~5 years)
License following
Phase 2 clinical data;
platform validation
Clinical data adds
value to partnered
programs
Targeted Radiopharmaceuticals Summit Europe 2023
Taxotere® was a blockbuster cancer drug
with peak global sales of >US$3B
despite having multiple US FDA “Black
Box” warnings
Advantages of DEP® docetaxel#*
Reduction in neutropenia; detergent-free
formulation; no steroid pre-treatment;
tumour-targeting (~60x more drug in
tumour); improved efficacy; improved
PK; patent filings to 2032 (plus up to an
additional ~5 years)
Utilise accelerated
development/reg. pathways
(i.e. 505(b)(2)) for optimal ROI
* Multiple preclinical studies have established improved efficacy,
survival and safety with DEP® with many different drugs
10
DEP® cabazitaxel: Positive Phase 2 results across
multiple tumour types, enhancing market potential
•
N=75, positive final results reported
Summary of key efficacy results
• Heavily pre-treated, advanced prostate cancer patients
(mCRPC)
• median progression-free survival (PFS) >50% longer,
median overall survival (OS) 10% longer than
published data for Jevtana® at same dose1
• Heavily pre-treated advanced, platinum-resistant ovarian
cancer patients
• disease control rate (DCR) 66.7%, objective response
rate (ORR) 17.6%, which compares favourably to
standard-of-care therapies that report ORRs ranging
from ~9 to 16%2,3,4
• Advanced gastro-oesophageal cancer patients
• median PFS and median OS 53.1% and 28.5% longer,
respectively, than similar patient cohorts treated with
standard-of-care paclitaxel5
Longer PFS and OS in prostate cancer patients treated with
DEP® cabazitaxel vs published data on Jevtana®
Key Efficacy Measures
DEP® cabazitaxel
(20 mg/m2)
(N=25†)
Jevtana®
(20 mg/m2)
(N=598†)1
Median PFS
4.4 months
2.9 months
Median overall survival (OS)
14.7 months
13.4 months
PSA Reduction ≥50%
52.4%
29.5%
Comparative bone marrow toxicity in prostate cancer patients
treated with DEP® cabazitaxel vs published data on Jevtana®
Safety Outcomes
DEP® cabazitaxel
(20 mg/m2)
(N=25^)
Jevtana®
(20 mg/m2)1
(N=580^)
Neutropenia* ≥ grade 3
16.0%
41.8%
Febrile neutropenia ≥ grade 3
0%
2.1%
Thrombocytopenia* ≥ grade 3
0%
2.6%
Neutropenic infection / sepsis
0%
2.1%
Results reported in Starpharma’s ASX Announcement dated 18 October 2023.
1 Eisenberger, M., et al., PROSELICA. J Clin Oncol, 2017, 35(28):3198-206
2 Taxol® (paclitaxel) Injection label, https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf
3 Mutch, DG, et al., J Clin Oncol, 2007;25(19):2811-2818.
4 Pujade-Lauraine, E, et al., J Clin Oncol, 2014;32(13):1302-1308.
5 Stockton, S, et al., The Oncologist, 2023;28(9):827–e822.
*Lab detected neutropenia or thrombocytopenia, regardless of whether the event was reported as an
All efficacy response data are for evaluable patients. Evaluable patients are those that received ≥1
adverse event; ^Safety population (received at least 1 dose)
dose cycle of DEP® cabazitaxel and had a CT scan, or other efficacy assessment (e.g., PSA in
prostate cancer) as applicable, to assess response to treatment at ≥~8 weeks after commencement
of treatment with DEP® cabazitaxel. PFS and safety data are reported for all patients who received
Targeted Radiopharmaceuticals Summit Europe 2023
treatment.
11
DEP® irinotecan Phase 2 trial
Positive interim results in multiple cancers
Monotherapy
in heavily pre-treated advanced
colorectal cancer (CRC) and
ovarian cancer patients
Heavily pre-treated CRC patients (N=38)
• >97% of patients had progressed after prior
treatment with conventional irinotecan
Positive interim results
• Durable efficacy responses for up to 72 weeks
with a DCR 48%
• No severe diarrhoea or cholinergic syndrome,
significantly fewer severe TRAEs
Heavily pre-treated ovarian patients (N=23)
• 100% of patients’ cancer resistant or refractory to
platinum-based therapies (standard-of-care)
Positive interim results
• DCR 100%, ORR 43% (Q2W)
• Tumour shrinkage of up to 60%
• Response durations up to 45 weeks
All efficacy response data reported are for evaluable patients. Evaluable patients are those
that received ≥1 dose cycle of DEP® irinotecan and had a CT scan to assess response to
treatment at ≥~8 weeks after commencement of treatment with DEP® irinotecan.
Tournigand et al., Clinical Oncology, 2023;41(19):3469-3477.
https://doi.org/10.1200/jco.22.02774
Combination arm
DEP®
irinotecan*
Camptosar®†^
Diarrhoea ≥ Gr 3
0
∼20-40%
Nausea ≥ Gr 3
2%
∼10%
Vomiting ≥ Gr 3
1%
∼10%
0%
~47%
Safety Outcome
with 5-fluorouracil (5-FU) and
leucovorin (LV) in advanced CRC
patients
GASTROINTESTINAL
Positive interim results (N=5)
• DCR 100%, ORR 20% (vs. published data in
advanced CRC patients – ORR of 4% for
conventional irinotecan plus 5-FU/LV (FOLFIRI)
as second-line therapy (i.e., less heavily pretreated patients))
• Clinicians report significant clinical benefit in
these heavily pre-treated patients, including
durable responses for up to 35 weeks
NERVOUS SYSTEM
Cholinergic
Syndrome
* N=112
• Very good tolerability
^ N=765
†H. Bleiberg. & E. Cvitkovic. (1996) Characterisation and Clinical
Management of CPT-11 (Irinotecan)-induced Adverse Events. European
Journal of Cancer, Volume 32 Supplement 3.
†https://www.medicines.org.uk/emc/product/6506- UK SmPC April 2022
“…Our experience in treating more than 20 patients on the trial to date have shown promisingly low rates
of severe gastrointestinal adverse events and absence of cholinergic toxicity, which are both common
and problematic side effects of standard irinotecan therapy.
“I am also getting consistent feedback from several patients in the trial that they far prefer DEP® irinotecan
plus 5-FU/LV compared to the standard FOLFIRI regimen, which uses conventional irinotecan.”
Dr Jenny Liu, MD, PhD, FRACP, Medical Oncologist and Principal Investigator
Kinghorn Cancer Centre, St Vincent’s Hospital in Sydney.
Targeted Radiopharmaceuticals Summit Europe 2023
12
Clinical validation of DEP® platform benefits
• >350 patients treated across 4 DEP® product clinical programs
• DEP® clinical-stage products span multiple drug classes
• Excellent translation from preclinical findings (PK, efficacy and safety)
• DEP® achieves tumour accumulation / targeting in humans: >60x higher vs. blood
• Improved or comparable efficacy, including responses in patients who failed
conventional formulations of these drugs
• Significantly lower rates or absence of severe AEs including:
o FDA “Black Box” warnings – neutropenia, anaphylaxis, severe diarrhoea
o cholinergic syndrome
o myelosuppression
• Well tolerated; no new AEs due to DEP® (TRAEs associated with delivered drug)
• Solubilisation beneficial in clinical settings, allowing for improved formulation
characteristics and clinical benefit (no polysorbate-80 infusion reactions, no steroids
required)
Targeted Radiopharmaceuticals Summit Europe 2023
13
Radiotheranostics and antibody-drug conjugates (ADCs)
Significant commercial activity continues
Radiotheranostics is a rapidly developing area of cancer
treatment and diagnosis
Innovative therapeutic area of ADCs continues to grow, with
many high-value deals signed in recent years
• Global radiopharmaceutical market projected to reach US$35 billion by
2031^
• The ADC market is expected to reach to more than US$15 billion by 2030*
• Over US$17 billion invested in M&A transactions between 2014 and June
2022+ in the radiopharmaceutical market
• Starpharma’s DEP® technology represents a valuable partnering platform
with potential to generate revenue through royalties and milestones
• Starpharma’s DEP® platform has yielded multiple radiotheranostic
DEP® candidates; Starpharma continues to evaluate licensing
opportunities for its internal radiotheranostic candidates and engages in
discussions with potential partners exploring access to Starpharma’s
DEP® platform
• Starpharma has two DEP® research agreements with MSD for dendrimerbased ADCs using the DEP® technology
• Significant scope to improve delivery, efficacy and safety profile of ADCs
Significant corporate deals in ADCs
Significant corporate deals in radiotheranostics
~US$2B
Nov 2022
US$3.9B
Oct 2017
€40M
Apr 2023
US$2.1B
Oct 2018
US$1B
Sept 2023
US$300M
Mar 2021
US$1.4B
Oct 2023
€520M
Dec 2021
US$1.7B
Feb 2022
US$936M
Jul 2022
US$1.1B
Feb 2023
US$4B + up
to US$22B
Oct 2023
US$6B
Jul 2020
US$2.75B
Nov 2020
€1.2B
Dec 2020
US$3.1B
Jun 2021
^MEDraysintell Nuclear medicine report Edition 2022
+https://www.medraysintell.com/_files/ugd/1beeab_6bc27b0bbe664527aca68f41bf7de2bc.pdf
*Colombo and Rich, The therapeutic window of antibody drug conjugates: A dogma in need of revision, Cancer Cell (2022),
https://doi.org/10.1016/j.ccell.2022.09.016
Targeted Radiopharmaceuticals Summit Europe 2023
14
Versatile DEP® platform for payload and targeting
flexibility
Starpharma’s versatile DEP® technology provides advantages, including targeting moiety
and payload flexibility, leading to enhanced safety and efficacy over conventional ADCs
+
Targeted Radiopharmaceuticals Summit Europe 2023
15
DEP® HER2-zirconium (radiodiagnostic): favourable imaging and
biodistribution in a HER2+ breast cancer model
DEP® HER2zirconium
DEP® HER2 can
be loaded with
imaging or
therapeutic
radionuclides
o HER2-targeted radiotheranostics development is less advanced compared to other targets, such as PSMA
o In clinical studies involving Trastuzumab, myelosuppression has emerged as a significant dose-limiting
toxicity
o DEP® HER2-zirconium showed enhanced biodistribution and kinetics in BT474 HER2+ tumour bearing mice:
→ Potential for the clinical delivery of higher doses to tumours with lower risk of dose-limiting toxicity
→ Highly desirable “fast-in”/”fast-out” kinetics, with rapid accumulation in tumour and rapid clearance
from the bloodstream
→ Excellent imaging contrast between tumour and normal tissues
Targeted Radiopharmaceuticals Summit Europe 2023
16
DEP® HER2 vs. Trastuzumab: PET/CT imaging performance
Trastuzumab-89Zr
DEP® HER2-89Zr
Trastuzumab-89Zr
DEP® HER2-89Zr
15
joint
%ID/g
joint
Tumour
joint
Tumour
day 2
Tumour
→ Higher levels of activity are observed in
heart for Trastuzumab at Day 2 and
Day 4, consistent with ex vivo blood
activ
Share your feedback
Discover